Skip to main content
Premium Trial:

Request an Annual Quote

VolitionRx, ImmuneHealth Collaborate on Prostate Cancer Study

NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with ImmuneHealth on a pilot study to asses the feasibility of VolitionRx's technology for detecting prostate cancer. 

In the study, which was initiated today, ImmuneHealth, a Belgian contract research organization, will use VolitionRx's NuQ assays to analyze 120 blood samples from patients across four Belgian hospitals. Four groups of patients will assessed — those with aggressive prostate cancer; those with indolent prostate cancer; those with prostate hyperplasia; and negative controls. 

The study will evaluate the ability of NuQ assays to detect prostate cancer and its ability to distinguish among the different prostate conditions and healthy samples. The assays are based on VolitionRx's Nucleosomics technology, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals in blood. 

Earlier this year, VolitionRx announced a deal with Singapore General Hospital for a pilot study of NuQ assays for detecting ovarian cancer. In December the Belgian firm also inked an agreement with the University of Bonn for a clinical study to evaluate the Nucleosomics platform for diagnosing lung cancer;, and in November, VolitionRx said it would collaborate with the University of Oxford on a clinical study to develop biomarkers for diagnosing endometriosis using the Nucleosomics platform.